Latest news

As an academic postdoc, opnMe provided me with the opportunity to apply my skills in a "semi-industry" setting. Collaborating with Boehringer Ingelheim’s experts on pharmacologically relevant questions in neuroscience was particularly exciting, as it aligns with my deep passion for the field.

opnMe represents a great concept of open science in two ways: It allows Boehringer to stimulate research at the forefront of scientific discovery within a well-defined disease area and it allows academics to excel by approaching Boehringer Ingelheim with proactive, innovative ideas.

It has been a pleasure for me to participate in opnMe. In addition to providing funding for our research project, it has given my lab an opportunity to collaborate with excellent people at Boehringer Ingelheim, generated some exciting results, and taught us new things about brain circuitry.

As an expert in SOS1/2 biology and tumorigenesis, I was pleased to see the opnMe call for novel hypotheses around SOS1::KRAS. It was the starting point that led to a productive research collaboration and now culminated into a high-profile publication.

I found the opnMe portal very easy to navigate and use. The application process is straightforward; this can be achieved in one afternoon. The time from submission to decision is one of the fastest turnarounds I have had, and this aspect makes a real difference in the momentum of pursuing a scientific idea.

opnMe has significantly advanced our research on the therapeutic potential of SOS1 deletion or inhibition in KRAS-driven and other RAS-dependent malignancies. By providing access to critical compounds, opnMe has enabled us to conduct studies that assess safety and efficacy of single and dual SOS1/SOS2 inhibition.

The investigation of pancreatic islet regeneration has been central to my lab's research. My collaboration with Boehringer Ingelheim, mediated by its open innovation portal opnMe, has provided us with access to unique reagents and resources and enabled rapid progress over the past two years.

opnMe has been instrumental in advancing our research in retinal diseases by providing access to a unique compound for IL1RAP inhibition and facilitating a successful partnership with Boehringer Ingelheim. Our experience with the team has been professional, enjoyable, and resulted in fruitful outcomes.

With the help of opnMe, we teamed up with Boehringer Ingelheim to develop a human-in-the-loop AI solution for pre-clinical research. We’re excited to see the tool in active use, having a measurable positive impact on the daily work of the scientists and increasing the safety of drug discovery.

opnMe helped us create a collaboration with a team at Boehringer that had designed an IDO inhibitor, leading to many fruitful interactions. It is a real team effort between my lab at Yale and the scientists at Boehringer. I am so hoping that this can lead to a true treatment for many patients.

opnMe has allowed us to showcase the potential of our novel subcutaneous drug delivery platform. They provided clinically relevant "beyond the rule of 5" compounds, which we successfully formulated. Their expert input during meetings was invaluable in advancing the research towards solving challenges of difficult to formulate compounds.

opnMe's expert guidance was pivotal in forging our research collaboration with Boehringer Ingelheim. Their initiative seamlessly bridged the gap between academic and industry research, uniting foundational biomedical science with application-oriented translational animal health research.

opnMe facilitated an efficient research partnership with Boehringer Ingelheim, accelerating the discovery of bioactive peptides. opnMe enabled us to combine expertise and resources, therefore leveraging the strengths of both organizations to achieve innovative outcomes.